Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
FAIL · Does not pass the screen
31.49 USD
Price as of 15 Sep 2026Daily close, not a live quoteLast reviewed 52 days ago
Screened 2026-09-15 · the tape above runs as of 18:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price31.49 USD at the 15 Sep 2026 close
Fair valueUnder review: its inputs are 51 days old.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price31.49 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Accumulation31.36+0.4% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Catalyst Pharmaceuticals, Inc. holds its Accumulation at $31.49. The statistical read favours the buyers, held for 32 days.
As held on the ledger · 2026-09-15
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 32 days
Price at the screen
$31.49
Valuation
18.20 trailing · 9.05 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.74
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.25%
Below 33%
Interest-bearing debt is just 0.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
75.69%
Below 49%
Money owed to the company is 75.7% of assets, above the 49% limit.
Fail
Revenue purity
4.20%
Below 5%
Only 4.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Catalyst Pharmaceuticals,'s business is fine, but its receivables are about 76% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CPRX's ethical verdict changes
Today CPRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Its inputs are 51 days old. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare Disease Drugmaker Offers Little Margin Of Safety
Picture a patient in the US finally getting reliable access to treatment for a muscle disorder that most doctors barely know. Catalyst Pharmaceuticals turns that need into a commercial product with 37% profit margins and 24% return on equity. Yet the shares sit just 2% below our fair value estimate, which is why the opportunity rating stays at none despite clearing the ethical screen.
The business trades on a forward multiple of 9 times earnings with only 6% revenue growth expected. Three analysts see a median target at the current price level, so the low multiple simply reflects modest expansion rather than a bargain. An unknown competitive moat leaves the durability of those margins open to question once any new rivals appear.
Biotech remains exposed to regulatory shifts and single-product concentration even in rare-disease niches. With growth this contained and the valuation already matched to fair value, the setup carries no real edge. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CPRX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Accumulation$31.49+0.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-10-15Accumulation$31.49+0.0%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-10-02Accumulation$31.49+0.0%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-08-25Accumulation$31.49+0.0%Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-07-25Accumulation$31.49+0.4%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-07-18Accumulation$31.36+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-07-03Accumulation$31.36+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$31.36Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
